Latanoprost Mylan Generics Italia (Latanoprost)

Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the eye’s ciliary body and scleral tissue. Activation of these receptors remodels the extracellular matrix, increasing uveoscleral outflow of aqueous humor, which reduces intraocular pressure and helps control glaucoma.

The dosing regimen for latanoprost is determined by the prescribing clinician. Typically, one drop of the ophthalmic solution is instilled once daily in the affected eye(s) in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety of latanoprost in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the risk. Breastfeeding mothers should consult their healthcare provider before using the medication.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally provides greater intraocular pressure reduction with once‑daily dosing compared with beta‑blocker or carbonic anhydrase inhibitor eye drops. It is often preferred for its efficacy and convenient dosing, though individual response and tolerance may vary.

Latanoprost ophthalmic solution should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep the cap tightly closed when not in use. Do not freeze the product.

Latanoprost is applied topically to the eye. The patient should wash their hands, tilt the head back, pull down the lower eyelid, and place a single drop into the conjunctival sac. The eye should be closed gently for a few seconds to aid absorption, avoiding contact with the bottle tip.

Serious but rare risks include severe eye inflammation such as uveitis or iritis, corneal edema, rapid loss of vision, and systemic allergic reactions that may present as swelling, rash, or anaphylaxis. Any sudden eye pain, vision change, or systemic symptoms should prompt immediate medical evaluation.

Latanoprost should not be used by individuals with known hypersensitivity to latanoprost or any component of the formulation. Caution is advised for patients with active ocular infections, severe inflammation, or recent ocular surgery until healing is confirmed. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.